A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2015
At a glance
- Drugs Iobenguane (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 25 Nov 2015 Status changed from discontinued to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Dec 2009 Planned end date changed from 1 Oct 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.